HRP20030653B1 - Novel benzoylguanidine salt - Google Patents

Novel benzoylguanidine salt

Info

Publication number
HRP20030653B1
HRP20030653B1 HRP20030653AA HRP20030653A HRP20030653B1 HR P20030653 B1 HRP20030653 B1 HR P20030653B1 HR P20030653A A HRP20030653A A HR P20030653AA HR P20030653 A HRP20030653 A HR P20030653A HR P20030653 B1 HRP20030653 B1 HR P20030653B1
Authority
HR
Croatia
Prior art keywords
salt
novel
novel benzoylguanidine
benzoylguanidine salt
benzoylguanidine
Prior art date
Application number
HRP20030653AA
Other languages
English (en)
Croatian (hr)
Inventor
Eickmeier Christian
Sieger Peter
K�rner Volkmar
Herter Rolf
Rall Werner
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of HRP20030653A2 publication Critical patent/HRP20030653A2/hr
Publication of HRP20030653B1 publication Critical patent/HRP20030653B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20030653AA 2001-02-15 2002-02-14 Novel benzoylguanidine salt HRP20030653B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz
PCT/EP2002/001535 WO2002064563A1 (de) 2001-02-15 2002-02-14 Neues benzoylguanidinsalz

Publications (2)

Publication Number Publication Date
HRP20030653A2 HRP20030653A2 (en) 2005-06-30
HRP20030653B1 true HRP20030653B1 (en) 2012-06-30

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20030653AA HRP20030653B1 (en) 2001-02-15 2002-02-14 Novel benzoylguanidine salt

Country Status (31)

Country Link
US (2) US20080025919A1 (enExample)
EP (1) EP1362030B1 (enExample)
JP (3) JP4408626B2 (enExample)
KR (1) KR100862176B1 (enExample)
CN (1) CN1222510C (enExample)
AT (1) ATE553078T1 (enExample)
AU (1) AU2002250939B2 (enExample)
BG (1) BG66330B1 (enExample)
BR (1) BR0207867A (enExample)
CA (1) CA2434829C (enExample)
CY (1) CY1112878T1 (enExample)
CZ (1) CZ303277B6 (enExample)
DE (1) DE10106970A1 (enExample)
DK (1) DK1362030T3 (enExample)
EA (1) EA006245B1 (enExample)
EC (1) ECSP034708A (enExample)
EE (1) EE200300393A (enExample)
ES (1) ES2385472T3 (enExample)
HR (1) HRP20030653B1 (enExample)
HU (1) HU230035B1 (enExample)
IL (1) IL156934A (enExample)
NO (1) NO20033299D0 (enExample)
NZ (1) NZ528081A (enExample)
PL (1) PL213300B1 (enExample)
PT (1) PT1362030E (enExample)
RS (1) RS52014B (enExample)
SI (1) SI1362030T1 (enExample)
SK (1) SK287830B6 (enExample)
UA (1) UA74625C2 (enExample)
WO (1) WO2002064563A1 (enExample)
ZA (1) ZA200305365B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017176A2 (de) * 1998-09-22 2000-03-30 Boehringer Ingelheim Pharma Kg Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017176A2 (de) * 1998-09-22 2000-03-30 Boehringer Ingelheim Pharma Kg Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln

Also Published As

Publication number Publication date
PL362129A1 (en) 2004-10-18
HU230035B1 (hu) 2015-05-28
BG108065A (bg) 2005-01-31
KR100862176B1 (ko) 2008-10-09
IL156934A (en) 2005-12-18
SK10202003A3 (sk) 2004-02-03
ES2385472T3 (es) 2012-07-25
YU61503A (sh) 2006-05-25
HRP20030653A2 (en) 2005-06-30
JP2009235097A (ja) 2009-10-15
EA006245B1 (ru) 2005-10-27
KR20030075197A (ko) 2003-09-22
CA2434829A1 (en) 2002-08-22
DK1362030T3 (da) 2012-07-09
JP4408626B2 (ja) 2010-02-03
PT1362030E (pt) 2012-07-04
AU2002250939B2 (en) 2007-09-06
EP1362030A1 (de) 2003-11-19
EA200300771A1 (ru) 2004-02-26
CN1491213A (zh) 2004-04-21
HUP0303027A2 (hu) 2003-12-29
BR0207867A (pt) 2004-03-23
NZ528081A (en) 2005-10-28
NO20033299L (no) 2003-07-22
JP5745215B2 (ja) 2015-07-08
PL213300B1 (pl) 2013-02-28
RS52014B (sr) 2012-04-30
SI1362030T1 (sl) 2012-07-31
SK287830B6 (sk) 2011-11-04
CY1112878T1 (el) 2016-04-13
CN1222510C (zh) 2005-10-12
BG66330B1 (bg) 2013-06-28
EE200300393A (et) 2003-12-15
US20080025919A1 (en) 2008-01-31
IL156934A0 (en) 2004-02-08
DE10106970A1 (de) 2002-08-29
CA2434829C (en) 2009-12-08
ATE553078T1 (de) 2012-04-15
CZ20032210A3 (cs) 2003-12-17
JP2013107906A (ja) 2013-06-06
US20080241077A1 (en) 2008-10-02
JP2004518721A (ja) 2004-06-24
HK1064093A1 (zh) 2005-01-21
NO20033299D0 (no) 2003-07-22
WO2002064563A1 (de) 2002-08-22
UA74625C2 (en) 2006-01-16
ZA200305365B (en) 2004-04-22
ECSP034708A (es) 2003-12-24
EP1362030B1 (de) 2012-04-11
HUP0303027A3 (en) 2010-04-28
CZ303277B6 (cs) 2012-07-11

Similar Documents

Publication Publication Date Title
ATE363463T1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
DK0931788T3 (da) Metalloproteasehæmmere
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
ATE403429T1 (de) Spiropyrazol-verbindungen
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
WO2004018449A8 (en) Piperidine-derivatives as pde4 inhibitors
MXPA05001354A (es) Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4.
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
NO20041075L (no) Ny 1, 2, 4-triazolforbindelse
BR0116217A (pt) Quinolonas antimicrobianas, composição farmacêutica, bem como aplicação farmacêutica das referidas quinolonas
SE0004245D0 (sv) Novel compounds and their use
PT1531672E (pt) Composições antimicrobianas
NO20034695D0 (no) Nye sammensetninger
SE0103710D0 (sv) Compounds
NO20054787L (no) Indenderivater som farmasotiske midler
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
DE60131960D1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5-thiazolcarboxamide enthalten
MY128164A (en) Compounds
HRP20030653B1 (en) Novel benzoylguanidine salt
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
DK1532111T3 (da) 2,5-disubstitueret 3-mercaptopentansyre
ATE294154T1 (de) Apfelsäureadditionssalze von terbinafin

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160202

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20170214